Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Myeloma
  • Chronic Lymphocytic Leukemia
  • Gynecologic Cancers
  • Genomic Testing
  • Melanoma
  • Genitourinary Cancers
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Dr. Michael A. Postow on the Treatment of Melanoma-Related Toxicities

March 11, 2016
By Michael A. Postow, MD
Video

Postow says there have been algorithms developed over recently years to determine patient's toxicities and prescribe certain immunosupressive treatments to help abate the symptoms.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering, discusses toxicities associated with checkpoint blockades. Postow says there have been algorithms developed over recently years to determine patient's toxicities and prescribe certain immunosupressive treatments to help abate the symptoms.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen


Optimizing Treatment Selection and Sequencing in Metastatic Melanoma

Optimizing Treatment Selection and Sequencing in Metastatic Melanoma

Targeted Oncology Staff
June 15th 2025
Article

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with metastatic melanoma.

Read More


Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen


Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Sabrina Serani
June 13th 2025
Article

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Read More


Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More

Related Content

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Unveiling the Unseen: The Future of Posttreatment Cancer Detection

Sabrina Serani
June 17th 2025
Article

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse prediction through innovative technologies and AI integration.

Read More


Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen


Optimizing Treatment Selection and Sequencing in Metastatic Melanoma

Optimizing Treatment Selection and Sequencing in Metastatic Melanoma

Targeted Oncology Staff
June 15th 2025
Article

During a live event, Ahmad Tarhini, MD, PhD, and participants discussed how to use combination immunotherapy in patients with metastatic melanoma.

Read More


Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen


Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Taletrectinib: A New Advance in ROS1-Mutant NSCLC

Sabrina Serani
June 13th 2025
Article

Taletrectinib emerges as a groundbreaking treatment for ROS1-mutant NSCLC, offering hope with its CNS activity and lower neurological side effects.

Read More


Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Cytoreductive Nephrectomy in the Era of Immunotherapy for Kidney Cancer

Jordyn Sava
June 12th 2025
Article

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.